Publications by authors named "Alexander E Perl"

Claim this Profile
I
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.
Mark J Levis, Mehdi Hamadani, Brent R Logan, Richard J Jones, Anurag K Singh, Alexander E Perl

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3-ITD measurable residual disease from the QuANTUM-First trial.
Mark J Levis, Harry P Erba, Pau Montesinos, Hee-Je Kim, Radovan Vrhovac, Alexander E Perl

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial.
Richard F Schlenk, Pau Montesinos, Hee-Je Kim, Antonio Romero-Aguilar, Radovan Vrhovac, Alexander E Perl

Haematologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3-Internal Tandem Duplications for Treatment With Quizartinib.
Jaime E Connolly Rohrbach, Ken C N Chang, Maha Karnoub, Li Liu, Yasser Mostafa Kamel, Alexander E Perl

Arch Pathol Lab Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.
Hetty E Carraway, Andrew M Brunner, Catherine E Lai, Marlise R Luskin, Jae Park, Alexander E Perl

Clin Lymphoma Myeloma Leuk· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.
Martha L Arellano, Michael J Thirman, John F DiPersio, Maël Heiblig, Eytan M Stein, Alexander E Perl

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Approaching a therapeutic inflection point for FLT3-mutated AML.
Alexander E Perl

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Mark J Levis, Mehdi Hamadani, Brent R Logan, Richard J Jones, Anurag K Singh, Alexander E Perl

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving racial/ethnic disparities in AML survival in the novel therapy era.
Xin Wang, Phyllis A Gimotty, Andrew H Matthews, Ronac Mamtani, Selina M Luger, Alexander E Perl

Blood Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 Trial.
Anand P Jillella, Sandra J Lee, Jessica K Altman, Selina M Luger, Martin S Tallman, Alexander E Perl

JAMA Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia.
Fiona C Brown, Xin Wang, Richard Birkinshaw, Chong Chyn Chua, Thomas Morley, Alexander E Perl

Blood Adv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine-mediated CAR T therapy resistance in AML.
Anand S Bhagwat, Leonel Torres, Olga Shestova, Maksim Shestov, Patrick W Mellors, Alexander E Perl

Nat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.
Betty K Hamilton, Bhavik J Pandya, Cristina Ivanescu, Dina Elsouda, Mehdi Hamadani, Alexander E Perl

Blood Adv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia.
Cheryl A C Peretz, Vanessa E Kennedy, Anushka Walia, Cyrille L Delley, Andrew Koh, Alexander E Perl

Nat Commun· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia.
Matthew P Connor, Neeharika Prathapa, Noelle V Frey, Saar I Gill, Elizabeth O Hexner, Alexander E Perl

Haematologica· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of .
Mark J Levis, Mehdi Hamadani, Brent Logan, Richard J Jones, Anurag K Singh, Alexander E Perl

J Clin Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.
Anthony D Sung, Thuy Koll, Shannon H Gier, Alessandro Racioppi, Griffin White, Alexander E Perl

Transplant Cell Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Yasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, Rory M Shallis, Andrew H Matthews, Alexander E Perl

Am J Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The FLT3 mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
Sunil K Joshi, Janét Pittsenbarger, Vanessa E Kennedy, Cheryl A C Peretz, Alexander E Perl

Am J Hematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
Keith W Pratz, Mohamad Cherry, Jessica K Altman, Brenda W Cooper, Nikolai A Podoltsev, Alexander E Perl

J Clin Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
Andrew H Matthews, Alexander E Perl, Selina M Luger, Saar I Gill, Catherine Lai

Am J Hematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Harry P Erba, Pau Montesinos, Hee-Je Kim, Elżbieta Patkowska, Radovan Vrhovac, Alexander E Perl

Lancet· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk Stratification.
Cheryl A C Peretz, Vanessa E Kennedy, Anushka Walia, Cyrille L Delley, Andrew Koh, Alexander E Perl

bioRxiv· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
Alexander E Perl, Richard A Larson, Nikolai A Podoltsev, Stephen Strickland, Eunice S Wang

Transplant Cell Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Matthew P Connor, Alison W Loren, Elizabeth O Hexner, Mary Ellen Martin, Saar I Gill, Alexander E Perl

Transplant Cell Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis